The CXCR4 antagonist BL-8040 in combination with the PD-1 inhibitor pembrolizumab (Keytruda) showed promising survival data in a phase IIa trial of patients with metastatic pancreatic adenocarcinoma (NCT02826486).
This study may serve as the gateway to immunotherapy for this population, according to lead investigator Manuel Hidalgo, MD, PhD. Read more . . .